BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wörns MA, Galle PR. Sorafenib for the treatment of hepatocellular carcinoma. Hepat Oncol 2014;1:189-204. [PMID: 30190954 DOI: 10.2217/hep.13.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017;67:173-83. [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
2 Lu T, Li C, Xiang C, Gong Y, Peng W, Chen C, Gas P. Overexpression of CISD1 Predicts Worse Survival in Hepatocarcinoma Patients. BioMed Research International 2022;2022:1-14. [DOI: 10.1155/2022/7823191] [Reference Citation Analysis]
3 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Huang CC, Chen HY, Chang RH, Liao PA, Lien HH, Hung CS, Yang SS, Hu JT. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015. Drug Des Devel Ther 2019;13:397-404. [PMID: 30774305 DOI: 10.2147/DDDT.S191334] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Lim H, Ramjeesingh R, Liu D, Tam VC, Knox JJ, Card PB, Meyers BM. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. J Natl Cancer Inst 2021;113:123-36. [PMID: 32898239 DOI: 10.1093/jnci/djaa119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]